- Graduate School - Duke University Medical Center (2013-2019)
- Fellowship - Duke University Medical Center (2012-2015), Hematology Oncology
- Residency - Duke University Medical Center (2009-2012), Internal Medicine
- Medical School - Harvard Medical School (2005-2009)
- Other Post Graduate Training - Duke University School of Medicine (2013-2019)
- Internship - Duke University (2009-2010)
Tian Zhang, M.D.
- Internal Medicine - Hematology/Oncology
- Genitourinary Cancer
- Kidney Cancer
New Patient Appointment Accepting Virtual Visits or 214-645-4673
Biography
Tian Zhang, M.D., M.H.S., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. Dr. Zhang was appointed Associate Director of Clinical Research in the Simmons Comprehensive Cancer Center in May 2024. She also serves as Director of Clinical Research within the Division of Hematology and Oncology in the Department of Internal Medicine. She specializes in the diagnosis and treatment of genitourinary malignancies, including kidney, prostate, bladder, and testicular cancers.
Dr. Zhang earned her medical degree from the Harvard-MIT Health Sciences and Technology (HST) program at Harvard Medical School. She completed a residency in internal medicine at Duke University, where she also received advanced training through a hematology-oncology fellowship. In addition, she earned a Master of Health Sciences in the Clinical Research Training Program at Duke in 2019.
Certified by the American Board of Internal Medicine in medical oncology, she joined the UT Southwestern faculty in 2021.
Dr. Zhang is an accomplished clinical trialist and translational researcher focused on evaluating clinical development of novel therapeutics and evaluating biomarkers for genitourinary malignancies. She has gained an international reputation developing clinical trials in kidney, prostate, and bladder cancers. Notably, she serves as the study chair for PDIGREE, an NCI-funded phase III trial in metastatic renal cell carcinoma and has activated many trials for patients at UT Southwestern.
Dr. Zhang is a member of several professional organizations, including the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the European Society for Medical Oncology (ESMO), the Society for Immunotherapy of Cancer (SITC), and the Chinese American Hematology and Oncology Network (CAHON).
She serves on numerous committees, including as Co-chair of the National Cancer Institute Genitourinary (GU) Steering Committee Renal Task Force. She is a member of several ASCO and SITC clinical management guidelines committees as well as the Alliance for Clinical Trials in Oncology GU Oncology and Immuno-Oncology Committees.
She brings a track record of research and mentoring to UT Southwestern. She has received multiple peer-reviewed grants, including notably the 2021 Cancer Prevention & Research Institute of Texas (CPRIT) Scholar Rising Stars Award, and as co-PI on DOD and NCI-funded grants. Her laboratory focuses on correlative and biomarker studies for patients with GU cancers.
Education & Training
Professional Associations & Affiliations
- American Society of Clinical Oncology
- American Association for Cancer Research
- European Society for Medical Oncology
- Society for Immunotherapy of Cancer
- Chinese American Hematologist and Oncologist Network
Honors & Awards
- ASCO Leadership Development Program 2023-2024
- CPRIT Scholar Rising Stars Award 2021, Cancer Prevention & Research Institute of Texas
- Resident Research Mentoring Award 2020, Duke Department of Medicine
- Women in Cancer Immunotherapy Network Leadership Institute 2019, SITC
- Duke LEADER Program 2018
- Methods in Clinical Cancer Research workshop 2014, AACR/ASCO
- Conquer Cancer Foundation Merit Award 2013, ASCO
- Molecular Biology in Clinical Oncology workshop 2013, AACR
- Medicine House Staff Community Service Award 2012, Duke University
- Phi Beta Kappa 2005, Columbia University
Books & Publications
-
Books
-
The search for the optimal immunotherapy sequencing in the perioperative setting of RCC in Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management
Karachaliou, G.S., Kaye, D.R., George, D.J., Zhang, T (2021), Springer -
Urologic Malignancies in Immune Checkpoint Inhibitors in Cancer
Harrison, M.R., Zhang, T., McNamara, M.A., Inman, B.A. (In Review), Edited by Fumito & Ernstoff -
Cancer of the Kidney in Abeloff’s Clinical Oncology, 6th Edition
McNamara, M.A., Zhang, T., Harrison, M.R., George, D.J. (2019), Elsevier -
Nanomedicines: Diagnostic and therapeutic applications in radiation oncology in Precision Radiation Oncology
Caster, J.M., Zhang, T., Patel, A.N., Newman, N.J., Wang, A.Z. (2018), Rutgers University Press -
Systemic Therapy for non-clear cell renal cell carcinoma in ASCO 2017 Educational Book
Zhang, T., Gong, J., Caitano, M., Pal, S.K. (2017) -
Management of metastatic prostate cancer in Evidence-Based Urology, 2nd Edition
Humeniuk, M., Zhang, T., McNamara, M.A., Ramalingam, S., Harrison, M.R. (2018), Wiley, BMJ Books -
Prostate cancer in Cancer Management Handbook, 17th Edition
Moul, J.W., Zhang, T., Armstrong, A.J., Lattanzi, J. (2015), UBM Medica, LLC -
Evolution of clinical states of castration resistant prostate cancer in Management of Castration Resistant Prostate Cancer
Zhang, T. & Armstrong, A.J. (2015), Springer -
Biochemical failure in prostate cancer in Comprehensive Textbook of Prostate Cancer
Zhang, T. & Wang, A.Z. (2011), Springer Science and Business Media
-
The search for the optimal immunotherapy sequencing in the perioperative setting of RCC in Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management
-
Publications
-
Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma.
Bhavsar NA, Harrison MR, Scales CD, Zhang T, Troy J, Ward K, Jabusch SM, Lampron Z, George DJ, European urology open science 2024 Aug 66 75-81 -
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.
Zhang T, Howard L, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell BA, Nordquist L, Rasmussen J, Riggan C, Reyes M, Davies C, Gray SR, Newman CR, Fernandez E, Ramalingam S, Harrison MR, George DJ, Wu Y, Armstrong AJ, European urology oncology 2024 Jul -
Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer.
Holland L, Bhanvadia R, Ibeziako N, Taylor J, Gerlt D, Chaplin I, Bagrodia A, Desai N, Gaston K, Lotan Y, Margulis V, Zhang T, Cole S, Woldu S, Urologic oncology 2024 Jul -
Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation.
Moore C, Naraine I, Zhang T, The oncologist 2024 Jun -
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma.
Gulati S, Barata PC, Elliott A, Bilen MA, Burgess EF, Choueiri TK, Darabi S, Dawson NA, Gartrell BA, Hammers HJ, Heath EI, Magee D, Rao A, Ryan CJ, Twardowski P, Wei S, Brugarolas J, Zhang T, Zibelman MR, Nabhan C, McKay RR, The Journal of clinical investigation 2024 May 134 14 -
Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2.
Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ, JU open plus 2024 Apr 2 4 -
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
Barata P, Gulati S, Elliott A, Hammers HJ, Burgess EF, Gartrell BA, Darabi S, Bilen MA, Basu A, Geynisman DM, Dawson NA, Zibelman MR, Zhang T, Wei S, Ryan CJ, Heath EI, Poorman KA, Nabhan C, McKay RR, The Journal of clinical investigation 2024 Apr -
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.
Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ, JU open plus 2024 Apr 2 4 -
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T, The New England journal of medicine 2024 Apr 390 15 1359-1371 -
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.
Fecteau RE, Koontz BF, Hoffman KE, Halabi S, Howard LE, Anand M, George DJ, Zhang T, Berry WR, Lee WR, Harrison MR, Corn PG, Armstrong AJ, Prostate cancer and prostatic diseases 2024 Feb -
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Lin CC, Garralda E, Schöffski P, Hong DS, Siu LL, Martin M, Maur M, Hui R, Soo RA, Chiu J, Zhang T, Ma B, Kyi C, Tan DS, Cassier PA, Sarantopoulos J, Weickhardt A, Carvajal RD, Spratlin J, Esaki T, Rolland F, Akerley W, Deschler-Baier B, Rispoli L, Samant TS, Chowdhury NR, Gusenleitner D, Kwak EL, Askoxylakis V, De Braud F, Oncoimmunology 2024 13 1 2290787 -
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A, Lichterman JN, Zhong JY, Shoag JE, Garcia JA, Zhang T, Barata PC, Human vaccines & immunotherapeutics 2023 Dec 19 3 2276629 -
Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis.
Hakimi K, Saidian A, Panian J, Barata P, Berg S, Chang SL, Saliby RM, Dzimitrowicz H, Emamekhoo H, Gross E, Kilari D, Lam E, Nguyen M, Meagher M, Wang L, Rauterkus GP, D'Andrea V, Yim K, Psutka S, Thapa B, Weise N, Zhang T, McKay RR, Derweesh IH, Clinical genitourinary cancer 2023 Dec 21 6 694-702 -
Genitourinary cancers updates: highlights from ASCO 2023.
Qin Q, Sheffield H, Taasan SM, Wang AZ, Zhang T, Journal of hematology & oncology 2023 Nov 16 1 112 -
Toxicity Management of Systemic Kidney Cancer Therapies.
Qin Q, Nein E, Flaten A, Zhang T, Hematology/oncology clinics of North America 2023 Oct 37 5 993-1003 -
The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
Atiq S, Hirshman N, Shariff A, Zhang T, Urologic oncology 2023 Oct 41 10 410-419 -
The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.
Agarwal N, Zhang T, Efstathiou E, Sayegh N, Engelsberg A, Saad F, Fizazi K, European journal of cancer (Oxford, England : 1990) 2023 Oct 192 113249 -
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.
Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, Berg S, Signoretti S, Lee Chang S, D'Andrea V, George D, Dzimitrowicz H, El Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus GP, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay RR, The oncologist 2023 Jun -
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.
Zhang T, Forde PM, Sullivan RJ, Sharon E, Barksdale E, Selig W, Ebbinghaus S, Fusaro G, Gunenc D, Battle D, Burns R, Hurlbert MS, Stewart M, Atkins MB, Journal for immunotherapy of cancer 2023 May 11 5 -
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
Autio KA, Higano CS, Nordquist L, Appleman LJ, Zhang T, Zhu XH, Babiker H, Vogelzang NJ, Prasad SM, Schweizer MT, Madan RA, Billotte S, Cavazos N, Bogg O, Li R, Chan K, Cho H, Kaneda M, Wang IM, Zheng J, Tang SY, Hollingsworth R, Kern KA, Petrylak DP, Journal for immunotherapy of cancer 2023 Mar 11 3 -
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
Shayeb AM, McManus HD, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan CL, Barata P, Bilen MA, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan MD, McGregor B, Choueiri TK, McKay RR, Clinical genitourinary cancer 2023 Feb 21 1 55-62 -
End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.
Dzimitrowicz HE, Wilson LE, Jackson BE, Spees LP, Baggett CD, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Leapman MS, Gross CP, Dinan MA, Wheeler SB, JCO oncology practice 2023 Feb 19 2 e213-e227 -
Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model.
Wang J, Sud S, Qu Y, Li L, Zhang J, Marron D, Knape NM, Kim IJ, Wagner KT, Zhang T, Zhao Y, Guo G, Wang AZ, Neoplasia (New York, N.Y.) 2022 Dec 36 100864 -
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC, Zhu J, Desai K, Kinsey E, Kao C, Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, Tafe LJ, Dayyani F, Gupta RT, McCall S, George DJ, Glenn ST, Nesline MK, George S, Zibelman M, Morrison C, Ornstein MC, Zhang T, Journal for immunotherapy of cancer 2022 Oct 10 10 -
Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.
Spees LP, Dinan MA, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George DJ, Scales CD, Pritchard JE, Leapman M, Gross CP, Wheeler SB, Clinical genitourinary cancer 2022 Oct 20 5 e396-e405 -
TISSUE ENGINEERED CANCER METASTASES AS CANCER VACCINE TO IMPROVE CANCER IMMUNOTHERAPY.
Sultanpuram NR, Ahmed U, Peters JT, Zhang T, Wang AZ, Acta biomaterialia 2022 Sep -
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.
Chen YW, Tucker MD, Brown LC, Yasin HA, Ancell KK, Armstrong AJ, Beckermann KE, Davis NB, Harrison MR, Kaiser EG, McAlister RK, Schaffer KR, Wallace DE, George DJ, Rathmell WK, Rini BI, Zhang T, Cancers 2022 Aug 14 15 -
Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC).
Dinan MA, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, Kaye D, George D, Scales CD, Baggett CD, Gross CP, Leapman MS, Wheeler SB, Urology 2022 Jul -
Facts and hopes for immunotherapy in renal cell carcinoma.
Yao C, Zhang T, Wu T, Brugarolas J, Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Jul -
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA, Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Jun JCO2200868 -
Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis.
Bu J, Jeong WJ, Jafari R, Kubiatowicz LJ, Nair A, Poellmann MJ, Hong RS, Liu EW, Owen RH, Rawding PA, Hopkins CM, Kim D, George DJ, Armstrong AJ, Král P, Wang AZ, Bruce J, Zhang T, Kimple RJ, Hong S, Biosensors & bioelectronics 2022 Jun 213 114445 -
Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
Pritchard JE, Wilson LE, Miller SM, Greiner MA, Cohen HJ, Kaye DR, Zhang T, Dinan MA, Journal of the American Geriatrics Society 2022 May -
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
Zhang T, Kephart J, Bronson E, Anand M, Daly C, Spasojevic I, Bakthavatsalam S, Franz K, Berg H, Karachaliou GS, James OG, Howard L, Halabi S, Harrison MR, Armstrong AJ, George DJ, The Prostate 2022 Mar -
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).
Harrison MR, Davis PG, Khouri MG, Bartlett DB, Gupta RT, Armstrong AJ, McNamara MA, Zhang T, Anand M, Onyenwoke K, Edwardson S, Craig D, Michalski M, Wu Y, Oyekunle T, Coyne B, Coburn A, Jones LW, George DJ, Prostate cancer and prostatic diseases 2022 Mar -
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
Brown LC, Halabi S, Somarelli JA, Humeniuk M, Wu Y, Oyekunle T, Howard L, Huang J, Anand M, Davies C, Patel P, Staats J, Weinhold KJ, Harrison MR, Zhang T, George DJ, Armstrong AJ, Prostate cancer and prostatic diseases 2022 Mar -
First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape.
Gulati S, Labaki C, Karachaliou GS, Choueiri TK, Zhang T, The oncologist 2022 Mar 27 2 125-134 -
Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.
Kaye DR, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, Pollack CE, George D, Scales CD, Baggett CD, Gross CP, Leapman MS, Wheeler SB, Dinan MA, Journal of geriatric oncology 2022 Feb -
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
Schöffski P, Tan DSW, Martín M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T, Prawira A, Akerley W, De Braud F, Hui R, Zhang T, Soo RA, Maur M, Weickhardt A, Krauss J, Deschler-Baier B, Lau A, Samant TS, Longmire T, Chowdhury NR, Sabatos-Peyton CA, Patel N, Ramesh R, Hu T, Carion A, Gusenleitner D, Yerramilli-Rao P, Askoxylakis V, Kwak EL, Hong DS, Journal for immunotherapy of cancer 2022 02 10 2 -
Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma.
Miller SM, Wilson LE, Greiner MA, Pritchard JE, Zhang T, Kaye DR, Cohen HJ, Becher RD, Maerz LL, Dinan MA, Journal of geriatric oncology 2022 Jan -
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu CY, Shyr Y, Armstrong AJ, Beer TM, Bijjula RR, Bilen MA, Connell CF, Dawsey SJ, Faller B, Gao X, Gartrell BA, Gill D, Gulati S, Halabi S, Hwang C, Joshi M, Khaki AR, Menon H, Morris MJ, Puc M, Russell KB, Shah NJ, Sharifi N, Shaya J, Schweizer MT, Steinharter J, Wulff-Burchfield EM, Xu W, Zhu J, Mishra S, Grivas P, Rini BI, Warner JL, Zhang T, Choueiri TK, Gupta S, McKay RR, JAMA network open 2021 11 4 11 e2134330 -
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
Tucker MD, Brown LC, Chen YW, Kao C, Hirshman N, Kinsey EN, Ancell KK, Beckermann KE, Davis NB, McAlister R, Schaffer K, Armstrong AJ, Harrison MR, George DJ, Rathmell WK, Rini BI, Zhang T, Biomarker research 2021 Nov 9 1 80 -
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Rose TL, Harrison MR, Deal AM, Ramalingam S, Whang YE, Brower B, Dunn M, Osterman CK, Heiling HM, Bjurlin MA, Smith AB, Nielsen ME, Tan HJ, Wallen E, Woods ME, George D, Zhang T, Drier A, Kim WY, Milowsky MI, Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Oct 39 28 3140-3148 -
Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics.
Msaouel P, Grivas P, Zhang T, European urology oncology 2021 Sep -
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
Brown LC, Desai K, Wei W, Kinsey EN, Kao C, George DJ, Rini BI, Ornstein MC, Zhang T, Journal for immunotherapy of cancer 2021 Sep 9 9 -
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees LP, Wheeler SB, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Leapman M, Gross CP, Dinan MA, Cancer medicine 2021 Sep -
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.
Desai K, Brown L, Wei W, Tucker M, Kao C, Kinsey E, Rini B, Beckermann K, Zhang T, Ornstein MC, Targeted oncology 2021 09 16 5 633-642 -
Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.
Brady-Nicholls R, Zhang J, Zhang T, Wang AZ, Butler R, Gatenby RA, Enderling H, Neoplasia (New York, N.Y.) 2021 Sep 23 9 851-858 -
Combination strategies to maximize the benefits of cancer immunotherapy.
Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX, Journal of hematology & oncology 2021 Sep 14 1 156 -
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
George DJ, Halabi S, Heath EI, Sartor AO, Sonpavde GP, Das D, Bitting RL, Berry W, Healy P, Anand M, Winters C, Riggan C, Kephart J, Wilder R, Shobe K, Rasmussen J, Milowsky MI, Fleming MT, Bearden J, Goodman M, Zhang T, Harrison MR, McNamara M, Zhang D, LaCroix BL, Kittles RA, Patierno BM, Sibley AB, Patierno SR, Owzar K, Hyslop T, Freedman JA, Armstrong AJ, Cancer 2021 Aug 127 16 2954-2965 -
Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
Wheeler SB, Spees LP, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Dinan MA, JCO oncology practice 2021 Jun OP2001082 -
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G, Annals of oncology : official journal of the European Society for Medical Oncology 2021 06 32 6 787-800 -
Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.
Zhang T, George DJ, Nature medicine 2021 04 27 4 586-588 -
Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.
Koontz BF, Hoffman KE, Halabi S, Healy P, Anand M, George DJ, Harrison MR, Zhang T, Berry WR, Corn PG, Lee WR, Armstrong AJ, International journal of radiation oncology, biology, physics 2021 Apr 109 5 1271-1278 -
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT, Cancer medicine 2021 04 10 7 2341-2349 -
An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).
Kao C, George DJ, Zhang T, The oncologist 2021 03 26 3 e508-e511 -
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
Brown LC, Tucker MD, Sedhom R, Schwartz EB, Zhu J, Kao C, Labriola MK, Gupta RT, Marin D, Wu Y, Gupta S, Zhang T, Harrison MR, George DJ, Alva A, Antonarakis ES, Armstrong AJ, Journal for immunotherapy of cancer 2021 03 9 3 -
Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Kao C, Powers E, Wu Y, Datto MB, Green MF, Strickler JH, Ready NE, Zhang T, Clarke JM, Clinical lung cancer 2021 Mar -
Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.
Dinan MA, Georgieva MV, Li Y, Zhang T, Harrison M, Shenolikar R, Scales CD, Journal of geriatric oncology 2021 03 12 2 298-304 -
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.
Hwang JK, Zhang T, Wang AZ, Li Z, Journal of hematology & oncology 2021 02 14 1 38 -
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Pal SK, Tangen C, Thompson IM, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN, Lancet (London, England) 2021 02 397 10275 695-703 -
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.
Zhang T, Agarwal A, Almquist RG, Runyambo D, Park S, Bronson E, Boominathan R, Rao C, Anand M, Oyekunle T, Healy P, McNamara MA, Ware K, Somarelli JA, George DJ, Armstrong AJ, Biomarker research 2021 Feb 9 1 14 -
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
Brown LC, Zhu J, Labriola MK, Wu Y, Cheris S, Liu X, Perkinson K, Su Z, McCall S, Huang J, Foo WC, Gupta RT, Armstrong AJ, George DJ, Harrison MR, Zhang T, Clinical genitourinary cancer 2020 Dec 18 6 509-513 -
The Immunotherapy Landscape in Renal Cell Carcinoma.
Brown LC, Desai K, Zhang T, Ornstein MC, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2020 Dec 34 6 733-748 -
Novel therapies are changing treatment paradigms in metastatic prostate cancer.
Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ, Armstrong AJ, Zhang T, Journal of hematology & oncology 2020 10 13 1 144 -
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Zhang T, Harrison MR, O'Donnell PH, Alva AS, Hahn NM, Appleman LJ, Cetnar J, Burke JM, Fleming MT, Milowsky MI, Mortazavi A, Shore N, Sonpavde GP, Schmidt EV, Bitman B, Munugalavadla V, Izumi R, Patel P, Staats J, Chan C, Weinhold KJ, George DJ, Cancer 2020 10 126 20 4485-4497 -
The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.
Brown LC, Zhang T, George DJ, Cancer journal (Sudbury, Mass.) 2020 Sep/Oct 26 5 376-381 -
Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.
Bakthavatsalam S, Wiangnak P, George DJ, Zhang T, Franz KJ, Bioorganic & medicinal chemistry letters 2020 06 30 11 127148 -
Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.
Brady-Nicholls R, Nagy JD, Gerke TA, Zhang T, Wang AZ, Zhang J, Gatenby RA, Enderling H, Nature communications 2020 04 11 1 1750 -
Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma.
Zhang T, George DJ, Clinical advances in hematology & oncology : H&O 2020 Apr 18 4 204-207 -
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK, Zhu J, Gupta R, McCall S, Jackson J, Kong EF, White JR, Cerqueira G, Gerding K, Simmons JK, George D, Zhang T, Journal for immunotherapy of cancer 2020 Mar 8 1 -
WOMENtorship: The #WomenInMedicine perspective.
Marshall AL, Dversdal RK, Murphy M, Prill DM, Zhang T, Jain S, Medical teacher 2020 02 42 2 228-230 -
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, Winters C, Riggan C, Rasmussen J, Wilder R, Stein M, Frizzell B, Harrison MR, Zhang T, Lee WR, Wu Y, Koontz BF, Armstrong AJ, European urology oncology 2020 Feb -
Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
Zhang T, Karsh LI, Nissenblatt MJ, Canfield SE, Clinical genitourinary cancer 2020 02 18 1 1-10 -
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.
Armstrong AJ, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Berry WR, Zhang T, Harrison MR, Lu C, Chen Y, Galletti G, Schonhoft JD, Scher HI, Wenstrup R, Tagawa ST, Antonarakis ES, George DJ, Halabi S, JCO precision oncology 2020 4 -
Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
Kinsey EN, Zhang T, Armstrong AJ, Cancer journal (Sudbury, Mass.) 2020 Jan/Feb 26 1 64-75 -
The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.
Zhang T, Hwang JK, George DJ, Pal SK, Cancer treatment and research communications 2020 24 100183 -
Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ, Urologic oncology 2019 11 37 11 813.e1-813.e9 -
Biologically Targeted Photo-Crosslinkable Nanopatch to Prevent Postsurgical Peritoneal Adhesion.
Mi Y, Yang F, Bloomquist C, Xia Y, Sun B, Qi Y, Wagner K, Montgomery SA, Zhang T, Wang AZ, Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2019 Oct 6 19 1900809 -
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ, Cancer medicine 2019 08 8 10 4644-4655 -
A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
Kao C, McNamara M, Alley C, Spector N, Jauhari S, Gupta RT, Zhang T, Zhu J, Clinical genitourinary cancer 2019 06 17 3 e672-e677 -
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
Labriola MK, Batich KA, Zhu J, McNamara MA, Harrison MR, Armstrong AJ, George DJ, Zhang T, Clinical genitourinary cancer 2019 06 17 3 e513-e521 -
Emerging therapeutic targets for patients with advanced prostate cancer.
Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA, Cancer treatment reviews 2019 Jun 76 1-9 -
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C Journal for immunotherapy of cancer 2019 Feb 7 1 27 -
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C Journal for immunotherapy of cancer 2019 Jan 7 1 18 -
The promise of immunotherapy in genitourinary malignancies.
Zhang T, Armstrong AJ, George DJ, Huang J, Precision clinical medicine 2018 Dec 1 3 97-101 -
Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.
Bakthavatsalam S, Sleeper ML, Dharani A, George DJ, Zhang T, Franz KJ, Angewandte Chemie (International ed. in English) 2018 09 57 39 12780-12784 -
Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.
Labriola M, Foo WC, George DJ, Zhang T, Clinical genitourinary cancer 2018 06 16 3 e509-e512 -
Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds.
Tian X, Werner ME, Roche KC, Hanson AD, Foote HP, Yu SK, Warner SB, Copp JA, Lara H, Wauthier EL, Caster JM, Herring LE, Zhang L, Tepper JE, Hsu DS, Zhang T, Reid LM, Wang AZ, Nature biomedical engineering 2018 06 2 6 443-452 -
Platinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk MS, Gupta RT, Healy P, McNamara M, Ramalingam S, Harrison M, George D, Zhang T, Wu Y, Armstrong AJ, Prostate cancer and prostatic diseases 2018 04 21 1 92-99 -
Multivalent binding and biomimetic cell rolling improves the sensitivity and specificity of circulating tumor cell capture.
Myung JH, Eblan MJ, Caster JM, Park S, Poellmann MJ, Wang K, Tepper JE, Tam KA, Miller SM, Shen C, Chen RC, Zhang T, Chera B, Wang AZ, Hong S Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Mar -
Clinical utility of non-EpCAM based circulating tumor cell assays.
Austin RG, Huang TJ, Wu M, Armstrong AJ, Zhang T, Advanced drug delivery reviews 2018 02 125 132-142 -
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI Journal for immunotherapy of cancer 2018 Jan 6 1 9 -
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T, Journal for immunotherapy of cancer 2018 01 6 1 4 -
Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.
Zhu J, Tucker M, Wang E, Grossman JS, Armstrong AJ, George DJ, Zhang T, Clinical genitourinary cancer 2017 12 15 6 e1137-e1141 -
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.
Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, DeSimone JM, Tepper JE, Vincent BG, Serody JS, Wang AZ Nature nanotechnology 2017 Jun -
Cabozantinib in genitourinary malignancies.
Zhang T, Park SE, Hong C, George DJ, Future oncology (London, England) 2017 Apr 13 8 755-765 -
Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.
Caster JM, Patel AN, Zhang T, Wang A, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2017 01 9 1 -
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.
Ramalingam S, Humeniuk MS, Hu R, Rasmussen J, Healy P, Wu Y, Harrison MR, Armstrong AJ, George DJ, Zhang T Urologic oncology 2017 Jan -
Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.
Tian X, Warner SB, Wagner KT, Caster JM, Zhang T, Ohana P, Gabizon AA, Wang AZ, International journal of radiation oncology, biology, physics 2016 11 96 3 547-55 -
Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer.
Tian J, Rodgers Z, Min Y, Wan X, Qiu H, Mi Y, Tian X, Wagner KT, Caster JM, Qi Y, Roche K, Zhang T, Cheng J, Wang AZ Nanomedicine : nanotechnology, biology, and medicine 2016 Nov -
Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.
Zhang T, Zhu J, George DJ, Nixon AB, Urologic oncology 2016 11 34 11 510-518 -
Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.
Shao Z, Wang AZ, George DJ, Zhang T, Asian journal of urology 2016 Oct 3 4 268-277 -
Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures.
Kamal A, Zhang T, Power S, Marcom PK, Journal of the National Comprehensive Cancer Network : JNCCN 2016 08 14 8 993-8 -
What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.
Hu R, George DJ, Zhang T, Therapeutic advances in urology 2016 Aug 8 4 272-278 -
Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.
Ware KE, Somarelli JA, Schaeffer D, Li J, Zhang T, Park S, Patierno SR, Freedman J, Garcia-Blanco MA, Armstrong AJ Oncotarget 2016 Jul -
Development of a Novel c-MET-Based CTC Detection Platform.
Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler JH, Abbruzzese JL, Harrison MR, Hsu DS, Healy P, Li J, Pi C, Prendergast KM, Hobbs C, Gemberling S, George DJ, Hurwitz HI, Connelly M, Garcia-Blanco MA, Armstrong AJ, Molecular cancer research : MCR 2016 06 14 6 539-47 -
Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM, Satterlee A, Min Y, Tian X, Kim YS, Caster JM, Zhang L, Zhang T, Huang L, Wang AZ Biomaterials 2016 Mar 82 178-93 -
A role for the androgen receptor in the treatment of male breast cancer.
Zhu J, Davis CT, Silberman S, Spector N, Zhang T, Critical reviews in oncology/hematology 2016 Feb 98 358-63 -
Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.
Zhang T, Armstrong AJ, Current oncology reports 2016 Jan 18 1 3 -
Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians.
Zhu J, Zhang T, Shah R, Kamal AH, Kelley MJ, Journal of cancer education : the official journal of the American Association for Cancer Education 2015 Dec 30 4 774-8 -
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ, Clinical genitourinary cancer 2015 Aug 13 4 392-399 -
Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
Zhang T, Zhu J, George DJ, Armstrong AJ, Expert opinion on pharmacotherapy 2015 Mar 16 4 473-85 -
Mismatch repair gone awry: Management of Lynch syndrome.
Zhang T, Boswell EL, McCall SJ, Hsu DS, Critical reviews in oncology/hematology 2015 Mar 93 3 170-9 -
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
Aggarwal R, Zhang T, Small EJ, Armstrong AJ, Journal of the National Comprehensive Cancer Network : JNCCN 2014 May 12 5 719-26 -
Standardizing and Evaluating Transitions of Care in the Era of Duty Hour Reform: One Institution's Resident-Led Effort.
Boggan JC, Zhang T, Derienzo C, Frush K, Andolsek K, Journal of graduate medical education 2013 Dec 5 4 652-7 -
Clinical phenotypes of castration-resistant prostate cancer.
Zhang T, Armstrong AJ, Clinical advances in hematology & oncology : H&O 2013 Nov 11 11 707-18 -
PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.
Zhang T, Das SK, Fels DR, Hansen KS, Wong TZ, Dewhirst MW, Vlahovic G, AJR. American journal of roentgenology 2013 Nov 201 5 W698-706 -
Prevalence and impact of correlative science in breast cancer phase II trials.
Zhang T, Schneider A, Hamilton EP, Patel K, Kamal AH, Lyman GH, Peppercorn JM, Breast cancer research and treatment 2013 Jun 139 3 845-50 -
Handoffs in the era of duty hours reform: a focused review and strategy to address changes in the Accreditation Council for Graduate Medical Education Common Program Requirements.
DeRienzo CM, Frush K, Barfield ME, Gopwani PR, Griffith BC, Jiang X, Mehta AI, Papavassiliou P, Rialon KL, Stephany AM, Zhang T, Andolsek KM Academic medicine : journal of the Association of American Medical Colleges 2012 Apr 87 4 403-10 -
Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.
Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ Biomaterials 2011 Nov 32 33
-
Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma.
Research
- Clinical investigation of novel and immune-based therapeutics
- Evaluation of prognostic and predictive biomarkers in genitourinary malignancies
- Translational evaluation of therapeutic targets in genitourinary malignancies
Clinical Focus
- Genitourinary Cancer
- Kidney Cancer
- Prostate Cancer
- Bladder Cancer
- Testicular Cancer
Results: 1 Locations
Genitourinary Cancer Clinic
at Cancer Care Outpatient Building 6202 Harry Hines Blvd., 9th FloorDallas, Texas 75235 (214) 645-4673 Directions to Genitourinary Cancer Clinic Parking Info for Genitourinary Cancer Clinic
New Patient Appointment Accepting Virtual Visits or 214-645-4673